Five things for pharma marketers to know: Monday, May 22, 2017

Share this content:


1. Romosozumab, an experimental osteoporosis drug being developed by Amgen and UCB, may raise the risk of heart attack by 30%. As a result, one analyst scrapped his financial models — which estimated the drug would peak at $800 million in sales annually.  (Forbes)

2. The FDA will hire 13 engineers, including software developers as well as A.I. and cloud computing experts, to create its new digital health business unit. Bakul Patel, associate center director for digital health at the agency, said hiring for these positions has been approved despite the Department of Health and Human Services' hiring freeze. (Wired)

3. Celgene's investigational multiple sclerosis drug, ozanimod, bested Biogen's Avonex in a head-to-head Phase-III trial. The Celgene drug reduced the rate of relapsing and remitting MS, when compared to Avonex, but did not perform better in disability progression. (Endpoints News)

4. The FDA is looking for additional comments on the issue of off-label communications, extending the comment period to July 18 from May 19. (FDA Law Blog)

5. President Trump's first budget proposal is expected to be announced on Tuesday and it likely includes major cuts to Medicaid and other safety-net programs, according to unnamed sources in The Washington Post. (WaPo)

Share this content:
Scroll down to see the next article